High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses
High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses
复制标题
DOI：
10.5588/ijtld.13.0075
复制
发表时间：
2014-10-01
影响因子：
4
通讯作者：
Van Deun, A.
中科院分区：
文献类型：
--
作者：
Piubello, A.;Harouna, S. Hassane;Van Deun, A.
单位：尼日尔国家结核病方案。达米恩基金会支持的地区。目的：评估短程标准化治疗方案对以前未接受二线药物治疗的多药耐药结核病(MDR-TB)患者的有效性。方法：前瞻性研究，纳入2008至2010年间登记的所有患者。为期12个月的标准化方案包括始终使用大剂量加替沙星、氯法齐明、乙胺丁醇和吡嗪酰胺，并在至少4个月的强化阶段辅以卡那霉素、丙硫酰胺和中高剂量异烟肼。患者在治疗开始时和每2个月进行一次痰涂片和培养监测。结果：65例耐多药肺结核患者入选病例进行分析。在58名接受人类免疫缺陷病毒感染检测的患者中，有一人呈阳性。25名患者(39.7%)受到严重影响(体重指数
SETTING: Niger National Tuberculosis Programme. Regions supported by the Damien Foundation.OBJECTIVE: To evaluate the effectiveness of a short-course standardised treatment regimen for patients with proven multidrug-resistant tuberculosis (MDR-TB) previously untreated with second-line drugs.METHODS: Prospective study including all patients enrolled from 2008 to 2010. The 12-month standardised regimen comprised high doses of gatifloxacin, clofazimine, ethambutol and pyrazinamide throughout, supplemented by kanamycin, prothionamide and medium-high doses of isoniazid during the intensive phase of a minimum of 4 months. Patients were monitored using sputum smear and culture at start of treatment and every 2 months. Cured patients were followed up 6-monthly for 24 months.RESULTS: Sixty-five patients with MDR-TB were included and analysed. One of 58 patients tested for human immunodeficiency virus (1.7%) infection was positive. Twenty-five patients (39.7%) were severely affected (body mass index